Activity Overview
Pharmacists are an integral part of the interdisciplinary team that is critical in the management of pain. Increasingly involved in many aspects of patient care, pharmacists are uniquely positioned to contribute substantially to pain management in all settings and throughout the continuum of care,from acute treatment through chronic pain management. Managing pain has remained a challenge despite the availability of analgesics and tools to assist healthcare professionals in optimizing patient care. With approximately 25 million people experiencing acute pain each year due to injuries or surgery, and over 76 million experiencing chronic pain in the United States, the assessment and management skills of pharmacists must be continually updated.

This activity has been designed to specifically meet the needs of practicing pharmacists and will address current topics, emerging treatment options, and breaking scientific news, including the use of methadone and QT prolongation, the US Food and Drug Administration decision on propoxyphene, and a review of the Drug Enforcement Administration regulation in the Controlled Substance Act of 1970 governing the role and obligations of pharmacists. Could you be charged along with the medical provider for inappropriate or excessive use of controlled substances? Yes.

This initiative has been designed to enhance community pharmacists’ understanding of the etiology and pharmacologic treatment of acute and chronic pain, to recognize drug-seeking behavior, to discover emerging therapies for the safe and effective treatment of pain, and to participate actively in the interdisciplinary team for optimal patient outcomes.

Intended Audience
This activity is designed for community pharmacists. No prerequisites required.

Learning Objectives
At the conclusion of this activity, the participant should be able to:

  • List 3 characteristics of acute and chronic pain, and the transitional stage in between.
  • Identify 2 barriers associated with opioid therapy (including addiction and pseudoaddiction) and methods to overcome these obstacles to optimize treatment.
  • Formulate strategies to address the clinical and psychological impact of inadequate pain management.

The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CE activity.

Accreditation Statement
The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education to provide continuing education for pharmacists.

Credit Designation Statement
The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this application-based educational activity will provide 1.5 contact hours credit (0.15 CEUs). Successful completion includes participating in the activity, completing a self-assessment instrument with a score of at least 70%, and completing an evaluation instrument. If you score less than 70% on the self-assessment instrument, you will be allowed to complete the examination one more time. ACPE Program # 064-000-09-206-L01-P.

The estimated time to complete this educational activity: 1.5 hours.

Release date: October 15, 2009. Expiration date: October 15, 2011.

Policy on Faculty and Provider Disclosure
As an accredited provider by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of The University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The faculty reported the following:

J. Richard Brown, PharmD, FASHP (Chair)
Colleges of Pharmacy and Medicine
University of Tennessee
Memphis, TN
Dr Brown reports having no relevant financial or advisory relationships with corporate organizations related to this activity.

Robert L. Barkin, PharmD, MBA, FCP, DAAPM
Professor, Rush Medical College
Faculty of Anesthesiology, Family Medicine, and Pharmacology
Rush University Medical Center
Clinical Pharmacologist
Northshore University Health System—Skokie, Evanston Hospitals, Pain Centers, and
 The Department of Anesthesiology
Chicago, IL
Dr Barkin reports serving as an educator (teaching, publishing, and lecturing) for Cypress, Dominion Diagnostics, Eli Lilly and Company, Endo Pharmaceuticals, Forrest Laboratories, PriCara, Sanofi-Aventis, and Wyeth.

Bruce R. Canaday, PharmD, FASHP, FAPhA
Clinical Professor and Vice-Chair
Division of Pharmacy Practice and Experiential Education
University of North Carolina Eshelman School of Pharmacy
Chapel Hill, NC
Dr Canaday reports having no relevant financial or advisory relationships with corporate organizations related to this activity.

Notice: In accordance with ACPE Criteria for Quality, the audience is advised that authors in this CE activity may include reference(s) to unlabeled, unapproved, or investigational uses of therapeutic agents or biomedical devices. The authors will inform the reader of when they discuss or reference an unapproved, unlabeled, or investigational use of therapeutic agent or biomedical device.

Disclaimer Statement
The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of University of Tennessee College of Pharmacy name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.

Grieveance Policy
A participant, sponsor, faculty member, or other individual wanting to file a grievance with respect to any aspect of an educational activity sponsored or cosponsored by The University of Tennessee College of Pharmacy may contact the Associate Dean for Continuing Education in writing. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.

Supported by an educational grant from PriCara, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., administered by Ortho-McNeil Janssen Scientific Affairs, LLC.
Step 1. Webcast

Step 2. Post-test

Home | Contact Us | View Account | Need Help? | Subscription